Objectives This study aimed to derive and validate a cut-off for severe disease activity (SDA) using the SLE Disease Activity Score (SLE-DAS) and compare its accuracy and impact on health-related ...

Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Fernando Arizpe et al. Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? Lupus Sci Med 2025;12:e001254. doi: ...

Unlike many other autoimmune diseases, in systemic lupus erythematosus (SLE) there are only two targeted biological therapies approved to choose between, namely belimumab and anifrolumab. Each is ...

Objective We investigated DORIS (Definition of Remission in SLE) attainment in patients with SLE in the placebo-controlled phase 3 TULIP long-term extension (LTE) trial of anifrolumab. DORIS ...

Objective This systematic review seeks to survey existing literature concerning systemic lupus erythematosus (SLE)-related thrombosis risk mechanisms within six pro-coagulable categories: ...

Purpose Activation of toll-like receptor (TLR)7/8 by self-RNA induces production of type I interferon and several other proinflammatory cytokines, which may contribute to the pathophysiology of SLE ...

Background The presence of anti-U1RNP is associated with the features of different systemic rheumatic diseases (SLE, SSc, etc.), and it is also included in the criteria of the mixed connective tissue ...

Background Administration of cytotoxic and immunosuppressive agents are well established treatment of systemic lupus erythematosus. However, the usage of these drugs shows frequent side effects.

Background Depression is one of the most frequent disorders in SLE, from 17% to 75% of prevalence, although subtle neuropsychiatric syndromes like symptoms of depressive and anxiety axes are often ...